What are the risks and the benefits of current and emerging weight-loss medications?

Current Diabetes Reports

Volumn 9, Issue 5, 2009, Pages 368-375

  Robinson, Jamie R ^a   Niswender, Kevin D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; AMIODARONE; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; BENZPHETAMINE; CANNABINOID 1 RECEPTOR ANTAGONIST; CETILISTAT; CYCLOSPORIN; EXENDIN 4; INSULIN; LIRAGLUTIDE; LORCASERIN; METFORMIN; PEPTIDE YY [3-36]; PHENDIMETRAZINE; PHENTERMINE; PLACEBO; PRAMLINTIDE; RIMONABANT; SERGLIFLOZIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SIBUTRAMINE; TARANABANT; TESOFENSINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; ZONISAMIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABNORMAL FECES; AGITATION; BINGE EATING DISORDER; BLOOD PRESSURE; BULIMIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; DEFECATION URGENCY; DEPRESSION; DIABETES MELLITUS; DIABETIC OBESITY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TARGETING; DRUG USE; DRUG WITHDRAWAL; EATING DISORDER; EPILEPSY; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSOMNIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LONG TERM CARE; MEMORY DISORDER; MENTAL DISEASE; MIGRAINE; MOOD CHANGE; NAUSEA; NIGHTMARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREATITIS; PANIC; PARESTHESIA; PSYCHOPATHY; REVIEW; RHINITIS; SEIZURE; SHORT COURSE THERAPY; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STEATORRHEA; SUICIDAL BEHAVIOR; SWEATING; SYSTEMIC DISEASE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VISUAL IMPAIRMENT; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; CYCLOBUTANES; HUMANS; LACTONES; OBESITY; WEIGHT LOSS;

EID: 70349745511     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0058-x     Document Type: Review

References (45)

1. World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Geneva: World Health Organization; 1998.
2. Idelevich E, Kirch W, Schindler C: Current pharmacotherapeutic concepts for the treatment of obesity in adults. Ther Adv Cardiovasc Dis 2009, 3:75-90.
3. Bray GA: Medications for weight reduction. Endocrinol Metab Clin North Am 2008, 37:923-942.
4. Chakrabarti R: PharmacEtherapy of obesity: emerging drugs and targets. Expert Opin Ther Targets 2009, 13:195-207.
5. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. National Institutes of Health [no authors listed]. Obes Res 1998, 6(Suppl 2):51S-209S.
6. Padwal RS, Majumdar SR:ODrug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007, 369:71-77.
7. Greenway FL, Caruso MK: Safety of obesity drugs. Expert Opin Drug Saf 2005, 4:1083-1095.
8. Sharma AM, Caterson ID, Coutinho W, et al.: Blood pressure changes associated with sibutramine and weight management: An analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes Obes Metab 2009, 11:239-250.
9. Bray GA: Drug treatment of obesity. Rev Endocr Metab Disord 2001, 2:403-418.
10. Gokcel A, Gumurdulu Y, Karakose H, et al.: Evaluation of the safety and efficacy of sibutramine, orlistat, and metformin in the treatment of obesity. Diabetes Obes Metab 2002, 4:49-55.
11. Philippe J, Raccah DH Treating type 2 diabetes: how safe are current therapeutic agents? Int J Clin Pract 2009, 63:321-332.
12. Hamnvik OR, McMahon GT: Balancing risk and benefit with oral hypoglycemic drugs. Mt Sinai J Med 2009, 76:234-243.
13. Park MH, Kinra S, Ward KJ, et al.: Metformin for obesity in children and adolescents: A systematic review. Diabetes Care 2009 Jun 5 (Epub ahead of print).
14. Carrizo E, Fernandez V, Connell L, et al.: Extended release metformin for metabolic control assistance during prolonged clozapine administration: A 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 2009, 113:19-26.
15. Barnett AH: New treatments inAtype 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol 2009, 70:343-353.
16. Blonde L, Klein EJ, Han J, et al.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447.
17. Bain SC, Stephens JW: Axenatide and pancreatitis: an update. Expert Opin Drug Saf 2008, 7:643-644.
18. Dore DD, Seeger JD, Arnold Chan K: Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009, 25:1019-1027.
19. Smith SR, Aronne LJ, Burns CM, et al.: Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008, 31:1816-1823.
20. Edelman S, Maier H, Wilhelm K: Pramlintide in the treatment of diabetes mellitus. BioDrugs 2008, 22:375-386.
21. Choussein S, Makri AA, Frangos CC, et al.: Effect of antiobesity medications in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:641-664.
22. Alberici A, Borroni B, Manelli F, et al.: Topiramate weight loss in migraine patients. J Neurol Sci 2009, 278:64-65.
23. Cates EC, Feldman JM, Boggs AA, et al.: Efficacy of add-on topiramate therapy in psychiatric patients with weight gain. Ann Pharmacother 2008, 42:505-510.
24. Klein KM, Theisen F, Knake S, et al.: Topiramate, nutrition and weight change: A prospective study. J Neurol Neurosurg Psychiatry 2008, 79:590-593.
25. McElroy SL, Guerdjikova AI, Martens B, et al.: Role of antiepileptic drugs in the management of eating disorders. CNS Drugs 2009, 23:139-156.
26. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2008, 13:383-392.
27. Tosches WA, Tisdell J: Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. Epilepsy Behav 2006, 8:522-526.
28. Anderson JW, Greenway FL, Fujioka K, et al.: Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial. Obes Res 2002, 10:633-641.
29. Aubin HJ: Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs 2002, 62:45-52.
30. Plodkowski RA, NguyeA Q, Sundaram U, et al.: Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother 2009, 10:1069-1081.
31. European Medicines Agency: The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf. Accessed June 2009.
32. Akbas F, Gasteyger C, Sjodin A, et al.: A critical review of the cannabinoid receptor as a drug target for obesity management. Obesity 2009, 10:58-67.
33. Aronne LJ, Pagotto U, Foster GD, Davis SN: The endocannabinoid system as a target for obesity treatment. Clin Cornerstone 2008, 9:52-66.
34. Astrup A, Madsbad S, Breum L, et al.: Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: A randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1906-1913.
35. Karra D, Chandarana K, Batterham R: The role of peptide YY in appetite regulation and obesity. J Physiol 2009, 587(Pt 1):19-25.
36. Neary FT, Batterham RL: Peptide YY: food for thought. Physiol Behav 2009, 97:616-619.
37. White Ne, Dhillo WS, Liu YL, et al.: Co-administration of SR141716 with peptide YY(3-36) or oxyntomodulin had additive effects on food intake in mice. Diabetes Obes Metab 2008, 10:167-170.
38. Neary NM, Small CJ, Druce MR, et al.: Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005, 146:5120-5127.
39. Degen L, Oesch S, Casanova M, et al.: Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005, 129:1430-1436.
40. Bryson A, de la Motte S, Dunk C: Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Br J Clin Pharmacol 2009, 67:309-315.
41. Smith SR, Prosser WA, Donahue DJ, et al.: Lorcaserin (APD356), a selective 5-HT2C agonist, reduces body weight in obese men and women. Obesity 2009, 17:494-503.
42. Thomsen WJ, Grottick AJ, Menzaghi F, et al.: Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: In vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008, 325:577-587.
43. VilsbolA T: Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc) 2009, 45:101-113.
44. Idris I, Donnelly R: Sodium-glucose coAtransporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009, 11:79-88.
45. Greenway FL, Whitehouse MJ, Guttadauria M, et al.: Rational design of a combination medication for the treatment of obesity. Obesity 2008, 17:30-39.